G. Stefanini, D. Holmes, and . Jr, Drug-Eluting Coronary-Artery Stents, New England Journal of Medicine, vol.368, issue.3, pp.254-65, 2013.
DOI : 10.1056/NEJMra1210816

T. Palmerini, G. Biondi-zoccai, D. Riva, D. Stettler, C. Sangiorgi et al., Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis, The Lancet, vol.379, issue.9824, pp.1393-402, 2012.
DOI : 10.1016/S0140-6736(12)60324-9

O. Marroquin, F. Selzer, S. Mulukutla, D. Williams, H. Vlachos et al., A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications, New England Journal of Medicine, vol.358, issue.4, pp.342-52, 2008.
DOI : 10.1056/NEJMoa0706258

S. Windecker, P. Kolh, F. Alfonso, J. Collet, J. Cremer et al., 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J, vol.35, pp.2541-619, 2014.

B. Xu, R. Gao, J. Wang, Y. Yang, S. Chen et al., A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon Versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis, JACC: Cardiovascular Interventions, vol.7, issue.2, pp.204-215, 2014.
DOI : 10.1016/j.jcin.2013.08.011

R. Byrne, F. Neumann, J. Mehilli, S. Pinieck, B. Wolff et al., Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial, The Lancet, vol.381, issue.9865, pp.461-467, 2013.
DOI : 10.1016/S0140-6736(12)61964-3

J. Wöhrle, M. Zadura, S. Möbius-winkler, M. Leschke, C. Opitz et al., SeQuent Please World Wide Registry, Journal of the American College of Cardiology, vol.60, issue.18, pp.1733-1738, 2012.
DOI : 10.1016/j.jacc.2012.07.040

U. Zeymer, M. Waliszewski, M. Spiecker, O. Gastmann, B. Faurie et al., Prospective ???real world??? registry for the use of the ???PCB only??? strategy in small vessel de novo lesions, Heart, vol.80, issue.(Suppl K), pp.311-317, 2014.
DOI : 10.1136/heartjnl-2013-304881

R. Mehran, G. Dangas, A. Abizaid, G. Mintz, A. Lansky et al., Angiographic Patterns of In-Stent Restenosis : Classification and Implications for Long-Term Outcome, Circulation, vol.100, issue.18, pp.1872-1880, 1999.
DOI : 10.1161/01.CIR.100.18.1872

D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen et al., Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions, Circulation, vol.115, issue.17, pp.2344-2351, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.685313

F. Kleber, D. Mathey, H. Rittger, and B. Scheller, How to use the drug-eluting balloon: recommendations by the German consensus group, EuroIntervention, vol.7, issue.K, pp.125-133, 2011.
DOI : 10.4244/EIJV7SKA21

G. Dangas, B. Claessen, A. Caixeta, E. Sanidas, G. Mintz et al., In-Stent Restenosis in the Drug-Eluting Stent Era, Journal of the American College of Cardiology, vol.56, issue.23, pp.1897-907, 2010.
DOI : 10.1016/j.jacc.2010.07.028

F. Alfonso, R. Byrne, F. Rivero, and A. Kastrati, Current Treatment of In-Stent Restenosis, Journal of the American College of Cardiology, vol.63, issue.24, pp.2659-73, 2014.
DOI : 10.1016/j.jacc.2014.02.545

F. Airoldi, M. Carlino, M. Montorfano, and A. Colombo, Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis, JACC Cardiovasc Interv, vol.4, pp.155-64, 2011.

F. Alfonso, M. Pérez-vizcayno, A. Cárdenas, G. D. Blanco, B. Seidelberger et al., A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal Stent???In-Stent Restenosis, Journal of the American College of Cardiology, vol.63, issue.14, pp.1378-86, 2014.
DOI : 10.1016/j.jacc.2013.12.006

J. Mehilli, R. Byrne, K. Tiroch, S. Pinieck, S. Schulz et al., Randomized Trial of Paclitaxel-Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis

F. Alfonso, M. Pérez-vizcayno, J. Dutary, J. Zueco, A. Cequier et al., Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug-Eluting Stent Restenosis, JACC: Cardiovascular Interventions, vol.5, issue.7, pp.728-765, 2012.
DOI : 10.1016/j.jcin.2012.03.017

. Bes=-biolimus-eluting-stent, EES= everolimus-eluting stent; LAD= left anterior descending artery; LCX= left circumflex; RCA= right coronary artery; SES= sirolimus-eluting stent; TIMI= thrombolysis in myocardial infarction; ZES= zotarolimus-eluting stent. Other abbreviations as in table 1. i Percentage of lesions with data available about target stent type

I. China, . Prospective, and . Multicenter, Randomized Trial of Paclitaxel-Coated Balloon versus Paclitaxel-Eluting Stent for the Treatment of Drug-eluting Stent In-Stent Restenosis; PEPCAD DES=Treatment of DES

. Catheter, TLR=Target lesion revascularization Other abbreviations as in tables 1, 2, 4 and 5. * Time of follow-up was 6 months for Habara et al 9, months for PEPCAD China ISR 13 and the GARO registry and 12 months for ISAR-DESIRE, p.14